{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-22-031997","form_type":"8-K/A","ticker":"ERNA","cik":"0000748592","company_name":"Ernexa Therapeutics Inc.","filed_at":"2022-09-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:58.071267+00:00","generated_at":"2026-06-23T18:08:52.192077+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Brooklyn ImmunoTherapeutics CSO Kevin D'Amour resigns; separation agreement provides $311K severance","bullets":["Dr. Kevin D'Amour's resignation as Chief Scientific Officer effective August 26, 2022.","Separation agreement includes 9 months' base salary totaling $311,250 (less withholdings).","Vested options on 57,296 shares exercisable for 90 days post-separation; all unvested equity forfeited.","COBRA health premium paid for the 9-month severance period.","D'Amour agrees to cooperation, non-disparagement, and a general release of claims."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-22-031997","json":"https://secwatch.observer/filing/0001140361-22-031997.json","markdown":"https://secwatch.observer/filing/0001140361-22-031997.md","text":"https://secwatch.observer/filing/0001140361-22-031997.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/748592/000114036122031997/0001140361-22-031997-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/748592/000114036122031997/brhc10041542_8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T18:08:52.192077+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7049d78010","claim":"Kevin D'Amour resigned as Chief Scientific Officer at Ernexa Therapeutics Inc..","evidence_excerpt":"On July 21, 2022, Dr. Kevin D’Amour, Chief Scientific Officer of Brooklyn ImmunoTherapeutics, Inc., a Delaware corporation (the “ Company ”), delivered his notice of resignation.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/748592/000114036122031997/0001140361-22-031997-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Scientific Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}